Our Mission
We aspire to radically improve health outcomes for all individuals with a female reproductive system through the development and commercialization of AI-powered gynecologic disease diagnostic solutions.
What We Do
Our data-driven approach delivers solutions that help women take control of their gynecologic health and empowers providers to deliver optimal care. We are using our decades of experience in ovarian cancer risk assessment to develop a cutting-edge portfolio of pelvic mass products.
Our History
Aspira Women's Health receives a Department of Defense Idea Development Grant
Aspira Women's Health receives a Department of Defense Idea Development Grant that funds the discovery of biomarkers that later lead to the development of the first ovarian cancer diagnostic tool.
Quest and Aspira Women's Health enter into a joint agreement
Quest and Aspira Women's Health enter into a joint agreement to accelerate the development and commercialization of Ova.
Aspira Women's Health completes an initial public offering
Aspira Women's Health completes an initial public offering of its stock on the Nasdaq stock exchange, trading under the symbol VRML.
Ova1 is the first- ever proteomic in vitro diagnostic multivariate index assay to be approved by the FDA
Ova1 is the first- ever proteomic in vitro diagnostic multivariate index assay to be approved by the FDA for clinical use for the assessment of ovarian cancer malignancy risk in women with pelvic masses when a surgical response is planned. Ova1 has a Negative Predictive Value (NPV) of 91%.
Overa – Aspira Women's Health's second generation blood-based ovarian cancer risk assessment
Overa – Aspira Women's Health's second generation blood-based ovarian cancer risk assessment with an improved Positive Predictive Value (PPV) of 79% is approved by the FDA.
Aspira Women's Health Announces OVA1® (MIA) and OVERA® (MIA2G)
Aspira Women's Health Announces OVA1® (MIA) and OVERA® (MIA2G) Study and Coverage by Clalit Health Services in Israel
First generation of OVAWatch manuscript published.
First generation of OVAWatch manuscript published in Future Oncology.
Ova1Plus launched
Ova1Plus launched to combine the sensitivity and specificity of Ova1 and Overa.
Aspira launches a distribution and co-marketing relationship
Aspira launches a distribution and co-marketing relationship with Bio-Reference Laboratories for Ova1Plus.
OvaWatch, the first of its kind lab developed test, is launched
OvaWatch, the first of its kind lab developed test, is launched. With a Negative Predictive Value (NPV) of 99%, allowing healthcare providers to confidently rule-out ovarian cancer in all women with pelvic masses as part of the initial clinical assessment.
Longitudinal Feature of OvaWatch launched
OvaWatch utilizes an AI-powered algorithm to assess malignancy risk of adnexal masses when initial clinical assessment indicates the mass is indeterminant or benign. With a negative predictive value of 99%, OvaWatch can now help physicians confidently determine the appropriate care plan over time.